Orthofix Medical
Orthofix Medical's revenue rose 2.9% to $822 million in fiscal 2025. Its operating margin was −9.9%, up from −10.6% a year earlier. Free cash flow was −$1 million. The diluted share count rose 3.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Orthofix Medical does
Orthofix is a medical device company based in Lewisville, Texas. It sells products used to treat bone and spine conditions: spinal implants and hardware, bone growth stimulation devices that help bones fuse or heal, limb reconstruction products, bone graft materials called biologics, and a surgical navigation system called 7D FLASH. Its customers are hospitals, ambulatory surgery centers and the surgeons who work in them.
It has two segments, Global Spine and Global Limb Reconstruction, which made up 84% and 16% of its net sales in 2025. Spine includes the bone growth therapies, spinal implants, biologics and navigation technology. It sells much of it worldwide through a network of distributors and sales representatives. It says it competes with many companies, several of which have more financial, manufacturing, marketing and technical resources.
Orthofix was founded in Verona, Italy, in 1980. In January 2023 it acquired SeaSpine in an all-stock merger, which now forms significant parts of its spinal implants, navigation and biologics lines. At December 31, 2025, it had 1,605 employees worldwide, 1,222 of them in the United States.
Its biggest risks, as it describes them
- Combining the legacy Orthofix and SeaSpine businesses may not deliver the benefits it expects.
- Hospital consolidation and purchasing groups may push for price cuts or leave it out as a supplier.
- It competes with larger device makers in an industry with fast technology change.
- It relies on a limited number of suppliers for some products and parts.
- Its bone graft products from donated human tissue face supply, regulatory and public-perception risks.
Income statement
From fiscal 2016 to 2020, earnings per share fell 6.5% a year and net income 5.2% a year, as new shares raised the share count by 5% and diluted each share's earnings. Orthofix Medical then lost money in fiscal 2021, 2022, 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 88 | 51 | 33 | 83 | 82 |
| Debt incl. finance leases | 20 | 20 | 114 | 175 | 175 |
| Net debt (negative means net cash) | −68 | −31 | 80 | 92 | 93 |
| Net debt to EBITDA | −3.2x | −2.0x | — | — | — |
| Debt to equity | 0.1x | 0.1x | 0.2x | 0.3x | 0.4x |
| Interest coverage | −5.5x | −9.5x | −24.0x | −5.0x | −4.7x |
| Current ratio | 2.5x | 3.1x | 2.5x | 2.6x | 2.5x |
| Quick ratio | 1.8x | 1.9x | 1.2x | 1.4x | 1.4x |
Cash flow
Projections
Project Orthofix Medical's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Orthofix Medical says to expect
- Full year 2026: net sales
Net sales are now expected to range from $825 million to $830 million, compared with prior guidance of $845 million to $855 million.
- Full year 2026: non-GAAP adjusted EBITDA
Non-GAAP adjusted EBITDA guidance is now expected to range from $86 million to $88 million, compared with prior guidance of $95 million to $98 million.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $4.1 million of Orthofix Medical shares on the open market, and 9 insiders sold $6.6 million, $1,408 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | Juniper Investment Company LLC10% owner | Sold | 190,000 | $8.86 | $1.7 million | Form 4 |
| Sep 18, 2026 | Juniper Investment Company LLC10% owner | Sold | 120,000 | $8.74 | $1.0 million | Form 4 |
| Sep 1, 2026 | Patrick FisherPresident, Global Limb Recon | Sold plan | 150 | $9.39 | $1,408 | Form 4 |
| Aug 18, 2026 | Patrick FisherPresident, Global Limb Recon | Sold | 1,295 | $10.09 | $13,067 | Form 4 |
| Aug 17, 2026 | Alexis P Michas10% owner | Sold | 20,000 | $10.01 | $200,200 | Form 4 |
| Aug 14, 2026 | Alexis P Michas10% owner | Sold | 19,500 | $10.38 | $202,410 | Form 4 |
| Jun 18, 2026 | Aviva McPherronPres, Global Ops & Qual | Sold | 3,670 | $9.38 | $34,425 | Form 4 |
| May 22, 2026 | Juniper Investment Company LLC10% owner | Sold | 242,000 | $10.70 | $2.6 million | Form 4 |
| May 7, 2026 | Engine Jet Capital L.P.10% owner | Bought | 30,000 | $12.18 | $365,500 | Form 4 |
| May 7, 2026 | John B Henneman IIIDirector | Bought | 5,000 | $12.26 | $61,300 | Form 4 |
| May 6, 2026 | Engine Jet Capital L.P.10% owner | Bought | 41,946 | $12.23 | $513,000 | Form 4 |
| May 5, 2026 | Engine Jet Capital L.P.10% owner | Bought | 112,950 | $11.99 | $1.4 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 9 | 5 of 9 | 5 of 9 |
| Rule of 40 | 47.9% | 5.9% | 2.7% |
| Altman Z'' | 2.20 | 1.65 | 1.02 |
| Accruals ratio | −15.3% | −16.7% | −14.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 2 of 9 | 5 of 9 | 5 of 9 |
Compare
Put Orthofix Medical side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Orthofix Medical | FY25 | 2.9% | −9.9% | −0.2% | −11.3% | — | 5 | |
| Varex Imaging | FY25 | 4.1% | −3.3% | 2.2% | −2.9% | — | 6 | Compare |
| Alphatec | FY25 | 24.9% | −10.8% | 0.4% | −14.3% | — | 5 | Compare |
| iRhythm | FY25 | 26.2% | −7.7% | 4.6% | −12.4% | — | 5 | Compare |
| Inspire Medical Systems | FY25 | 13.6% | 5.6% | 8.6% | 14.2% | −4.8x | 5 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 410 | 434 | 453 | 460 | 407 | 464 | 461 | 747 | 800 | 822 |
| Revenue growth | 3.4% | 5.9% | 4.4% | 1.5% | −11.6% | 14.2% | −0.8% | 62.1% | 7.1% | 2.9% |
| Gross profit | 322 | 341 | 356 | 359 | 305 | 350 | 337 | 486 | 546 | 566 |
| Research and development | 29 | 30 | 33 | 35 | 39 | 50 | 49 | 80 | 74 | 66 |
| Operating income | 21 | 41 | 30 | −19 | −6 | −8 | −13 | −139 | −85 | −81 |
| Net income | 3 | 6 | 14 | −28 | 2 | −38 | −20 | −151 | −126 | −92 |
| Diluted EPS (US$) | 0.17 | 0.34 | 0.72 | −1.51 | 0.13 | −1.95 | −0.98 | −4.12 | −3.30 | −2.33 |
| Diluted shares (millions) | 18 | 18 | 19 | 19 | 19 | 20 | 20 | 37 | 38 | 40 |
| Cash flow | ||||||||||
| Cash from operations | 59 | 39 | 50 | 32 | 74 | 18 | −12 | −46 | 26 | 33 |
| Capital expenditure | 16 | 15 | 14 | 19 | 16 | 18 | 21 | 60 | 35 | 35 |
| Free cash flow | 43 | 24 | 36 | 13 | 59 | 1 | −33 | −106 | −9 | −1 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 63 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 44 | 0 | 18 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 16 | 13 | 19 | 22 | 16 | 15 | 18 | 36 | 32 | 29 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 40 | 81 | 70 | 70 | 96 | 88 | 51 | 33 | 83 | 82 |
| Debt incl. finance leases | 0 | 0 | 0 | 21 | 23 | 20 | 20 | 114 | 175 | 175 |
| Total assets | 372 | 405 | 467 | 496 | 526 | 477 | 459 | 925 | 893 | 851 |
| Total liabilities | 109 | 109 | 131 | 168 | 169 | 140 | 122 | 327 | 390 | 401 |
| Shareholders' equity | 264 | 297 | 335 | 328 | 357 | 337 | 337 | 599 | 503 | 450 |
| Margins and ratios | ||||||||||
| Gross margin | 78.6% | 78.5% | 78.7% | 78.1% | 74.9% | 75.3% | 73.2% | 65.1% | 68.3% | 68.8% |
| Operating margin | 5.1% | 9.4% | 6.6% | −4.1% | −1.5% | −1.8% | −2.9% | −18.6% | −10.6% | −9.9% |
| Net margin | 0.8% | 1.4% | 3.0% | −6.2% | 0.6% | −8.3% | −4.3% | −20.3% | −15.8% | −11.2% |
| Free cash flow margin | 10.4% | 5.6% | 8.0% | 2.8% | 14.5% | 0.1% | −7.1% | −14.2% | −1.1% | −0.2% |
| Rule of 40 (growth + FCF margin) | 13.8% | 11.5% | 12.4% | 4.4% | 2.9% | 14.4% | −8.0% | 47.9% | 5.9% | 2.7% |
| Return on capital | 4.7% | 9.3% | 7.5% | −5.5% | −1.8% | −2.4% | −3.6% | −22.3% | −10.5% | −11.3% |
| Return on equity | 1.1% | 2.2% | 4.4% | −8.6% | 0.7% | −11.1% | −5.9% | −32.4% | −22.9% | −19.3% |
| Return on assets | 0.8% | 1.6% | 3.2% | −5.9% | 0.5% | −7.7% | −4.2% | −21.9% | −13.9% | −10.6% |
| Net debt to EBITDA | −0.9x | −1.3x | −1.4x | −8.2x | −3.0x | −3.2x | −2.0x | — | — | — |